Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1999 Jun 15;340(Pt 3):569–577.

The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core.

J Schalkwijk 1, O Wiedow 1, S Hirose 1
PMCID: PMC1220286  PMID: 10359639

Abstract

Recently, several new genes have been discovered in various species which are homologous to the well-characterized human epithelial proteinase inhibitor elafin/SKALP (skin-derived anti-leukoproteinase). Because of the high degree of conservation and the similarities in genomic organization, we propose that these genes belong to a novel gene family. At the protein level, the family members are defined by: (1) an N-terminal domain consisting of a variable number of repeats with the consensus sequence Gly-Gln-Asp-Pro-Val-Lys that can act as an anchoring motif by transglutaminase cross-linking, and (2) a C-terminal four-disulphide core or whey acidic protein (WAP) domain, which harbours a functional motif involved in binding of proteinases and possibly other proteins. We have proposed the name trappin gene family as a unifying nomenclature for this group of proteins (trappin is an acronym for TRansglutaminase substrate and wAP domain containing ProteIN, and refers to its functional property of 'getting trapped' in tissues by covalent cross-linking). Analysis of the trappin family members shows extensive diversification in bovidae and suidae, whereas the number of primate trappins is probably limited. Recent biochemical and cell biological data on the human trappin family member elafin/SKALP suggest that this molecule is induced in epidermis by cellular stress. We hypothesize that trappins play an important role in the regulation of inflammation and in protection against tissue damage in stratified epithelia.

Full Text

The Full Text of this article is available as a PDF (278.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alkemade H. A., de Jongh G. J., Arnold W. P., van de Kerkhof P. C., Schalkwijk J. Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A. J Invest Dermatol. 1995 Feb;104(2):189–193. doi: 10.1111/1523-1747.ep12612749. [DOI] [PubMed] [Google Scholar]
  2. Alkemade H., van de Kerkhof P., Schalkwijk J. Demonstration of skin-derived antileukoproteinase (SKALP) in urine of psoriatic patients. J Invest Dermatol. 1992 Jul;99(1):3–7. doi: 10.1111/1523-1747.ep12611375. [DOI] [PubMed] [Google Scholar]
  3. Alkemade J. A., Molhuizen H. O., Ponec M., Kempenaar J. A., Zeeuwen P. L., de Jongh G. J., van Vlijmen-Willems I. M., van Erp P. E., van de Kerkhof P. C., Schalkwijk J. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci. 1994 Aug;107(Pt 8):2335–2342. doi: 10.1242/jcs.107.8.2335. [DOI] [PubMed] [Google Scholar]
  4. Araki K., Kuroki J., Ito O., Kuwada M., Tachibana S. Novel peptide inhibitor (SPAI) of Na+, K+-ATPase from porcine intestine. Biochem Biophys Res Commun. 1989 Oct 16;164(1):496–502. doi: 10.1016/0006-291x(89)91747-6. [DOI] [PubMed] [Google Scholar]
  5. Bairoch A., Bucher P., Hofmann K. The PROSITE database, its status in 1997. Nucleic Acids Res. 1997 Jan 1;25(1):217–221. doi: 10.1093/nar/25.1.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen Y., Pioli D., Piper P. W. Overexpression of the gene for polyubiquitin in yeast confers increased secretion of a human leucocyte protease inhibitor. Biotechnology (N Y) 1994 Aug;12(8):819–823. doi: 10.1038/nbt0894-819. [DOI] [PubMed] [Google Scholar]
  7. Cowan B., Baron O., Crack J., Coulber C., Wilson G. J., Rabinovitch M. Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation. J Clin Invest. 1996 Jun 1;97(11):2452–2468. doi: 10.1172/JCI118692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Drenth J., Low B. W., Richardson J. S., Wright C. S. The toxin-agglutinin fold. A new group of small protein structures organized around a four-disulfide core. J Biol Chem. 1980 Apr 10;255(7):2652–2655. [PubMed] [Google Scholar]
  9. Eckert R. L., Crish J. F., Robinson N. A. The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Physiol Rev. 1997 Apr;77(2):397–424. doi: 10.1152/physrev.1997.77.2.397. [DOI] [PubMed] [Google Scholar]
  10. Francart C., Dauchez M., Alix A. J., Lippens G. Solution structure of R-elafin, a specific inhibitor of elastase. J Mol Biol. 1997 May 9;268(3):666–677. doi: 10.1006/jmbi.1997.0983. [DOI] [PubMed] [Google Scholar]
  11. Franzke C. W., Baici A., Bartels J., Christophers E., Wiedow O. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J Biol Chem. 1996 Sep 6;271(36):21886–21890. doi: 10.1074/jbc.271.36.21886. [DOI] [PubMed] [Google Scholar]
  12. Furukawa M., Suzuki Y., Ghoneim M. A., Tachibana S., Hirose S. Cryptic origin of SPAI, a plasma protein with a transglutaminase substrate domain and the WAP motif, revealed by in situ hybridization and immunohistochemistry. J Biol Chem. 1996 Nov 22;271(47):29517–29520. doi: 10.1074/jbc.271.47.29517. [DOI] [PubMed] [Google Scholar]
  13. Furutani Y., Kato A., Yasue H., Alexander L. J., Beattie C. W., Hirose S. Evolution of the trappin multigene family in the Suidae. J Biochem. 1998 Sep;124(3):491–502. doi: 10.1093/oxfordjournals.jbchem.a022140. [DOI] [PubMed] [Google Scholar]
  14. Gadek J. E., Pacht E. R. The interdependence of lung antioxidants and antiprotease defense in ARDS. Chest. 1996 Dec;110(6 Suppl):273S–277S. doi: 10.1378/chest.110.6_supplement.273s. [DOI] [PubMed] [Google Scholar]
  15. Greenberg C. S., Birckbichler P. J., Rice R. H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991 Dec;5(15):3071–3077. doi: 10.1096/fasebj.5.15.1683845. [DOI] [PubMed] [Google Scholar]
  16. Grütter M. G., Fendrich G., Huber R., Bode W. The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J. 1988 Feb;7(2):345–351. doi: 10.1002/j.1460-2075.1988.tb02819.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hagstrom J. E., Fautsch M. P., Perdok M., Vrabel A., Wieben E. D. Exons lost and found. Unusual evolution of a seminal vesicle transglutaminase substrate. J Biol Chem. 1996 Aug 30;271(35):21114–21119. doi: 10.1074/jbc.271.35.21114. [DOI] [PubMed] [Google Scholar]
  18. Kennedy A. J., Cline A., Ney U. M., Johnson W. H., Roberts N. A. The effect of a peptide aldehyde reversible inhibitor of elastase on a human leucocyte elastase-induced model of emphysema in the hamster. Eur J Respir Dis. 1987 Nov;71(5):472–478. [PubMed] [Google Scholar]
  19. Klasen E. C., Kramps J. A. The N-terminal sequence of antileukoprotease isolated from bronchial secretion. Biochem Biophys Res Commun. 1985 Apr 16;128(1):285–289. doi: 10.1016/0006-291x(85)91676-6. [DOI] [PubMed] [Google Scholar]
  20. Kuijpers A. L., Zeeuwen P. L., de Jongh G. J., van de Kerkhof P. C., Alkemade H. A., Schalkwijk J. Skin-derived antileukoproteinase (SKALP) is decreased in pustular forms of psoriasis. A clue to the pathogenesis of pustule formation? Arch Dermatol Res. 1996 Oct;288(11):641–647. doi: 10.1007/BF02505272. [DOI] [PubMed] [Google Scholar]
  21. Kuroki J., Hosoya T., Itakura M., Hirose S., Tamechika I., Yoshimoto T., Ghoneim M. A., Nara K., Kato A., Suzuki Y. Cloning, characterization, and tissue distribution of porcine SPAI, a protein with a transglutaminase substrate domain and the WAP motif. J Biol Chem. 1995 Sep 22;270(38):22428–22433. doi: 10.1074/jbc.270.38.22428. [DOI] [PubMed] [Google Scholar]
  22. Lorand L., Conrad S. M. Transglutaminases. Mol Cell Biochem. 1984;58(1-2):9–35. doi: 10.1007/BF00240602. [DOI] [PubMed] [Google Scholar]
  23. Lundwall A., Lazure C. A novel gene family encoding proteins with highly differing structure because of a rapidly evolving exon. FEBS Lett. 1995 Oct 23;374(1):53–56. doi: 10.1016/0014-5793(95)01076-q. [DOI] [PubMed] [Google Scholar]
  24. Lundwall A. The cloning of a rapidly evolving seminal-vesicle-transcribed gene encoding the major clot-forming protein of mouse semen. Eur J Biochem. 1996 Jan 15;235(1-2):424–430. doi: 10.1111/j.1432-1033.1996.00424.x. [DOI] [PubMed] [Google Scholar]
  25. Lundwall A., Ulvsback M. The gene of the protease inhibitor SKALP/elafin is a member of the REST gene family. Biochem Biophys Res Commun. 1996 Apr 16;221(2):323–327. doi: 10.1006/bbrc.1996.0594. [DOI] [PubMed] [Google Scholar]
  26. Molhuizen H. O., Alkemade H. A., Zeeuwen P. L., de Jongh G. J., Wieringa B., Schalkwijk J. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem. 1993 Jun 5;268(16):12028–12032. [PubMed] [Google Scholar]
  27. Molhuizen H. O., Schalkwijk J. Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol Chem Hoppe Seyler. 1995 Jan;376(1):1–7. doi: 10.1515/bchm3.1995.376.1.1. [DOI] [PubMed] [Google Scholar]
  28. Molhuizen H. O., Zeeuwen P. L., Olde Weghuis D., Geurts van Kessel A., Schalkwijk J. Assignment of the human gene encoding the epidermal serine proteinase inhibitor SKALP (PI3) to chromosome region 20q12-->q13. Cytogenet Cell Genet. 1994;66(2):129–131. doi: 10.1159/000133683. [DOI] [PubMed] [Google Scholar]
  29. Nara K., Ito S., Ito T., Suzuki Y., Ghoneim M. A., Tachibana S., Hirose S. Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". J Biochem. 1994 Mar;115(3):441–448. doi: 10.1093/oxfordjournals.jbchem.a124357. [DOI] [PubMed] [Google Scholar]
  30. Nonomura K., Yamanishi K., Yasuno H., Nara K., Hirose S. Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. J Invest Dermatol. 1994 Jul;103(1):88–91. doi: 10.1111/1523-1747.ep12391802. [DOI] [PubMed] [Google Scholar]
  31. Pfundt R., van Ruissen F., van Vlijmen-Willems I. M., Alkemade H. A., Zeeuwen P. L., Jap P. H., Dijkman H., Fransen J., Croes H., van Erp P. E. Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J Clin Invest. 1996 Sep 15;98(6):1389–1399. doi: 10.1172/JCI118926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Powers J. C., Bengali Z. H. Elastase inhibitors for treatment of emphysema. Approaches to synthesis and biological evaluation. Am Rev Respir Dis. 1986 Nov;134(5):1097–1100. doi: 10.1164/arrd.1986.134.5.1097. [DOI] [PubMed] [Google Scholar]
  33. Robinson P. A., Leek J. P., Carr I. M., Bailey A., Lench N. J., Morrison J., Hume W. J., High A. S., Markham A. F. Yeast artificial chromosome cloning and chromosomal localization of the abundant odontogenic keratocyst protein elafin. Arch Oral Biol. 1996 May;41(5):445–452. doi: 10.1016/0003-9969(95)00150-6. [DOI] [PubMed] [Google Scholar]
  34. Rudolphus A., Kramps J. A., Mauve I., Dijkman J. H. Intratracheally-instilled antileukoprotease and alpha 1-proteinase inhibitor: effect on human neutrophil elastase-induced experimental emphysema and pulmonary localization. Histochem J. 1994 Oct;26(10):817–824. [PubMed] [Google Scholar]
  35. Saheki T., Ito F., Hagiwara H., Saito Y., Kuroki J., Tachibana S., Hirose S. Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. Biochem Biophys Res Commun. 1992 May 29;185(1):240–245. doi: 10.1016/s0006-291x(05)80981-7. [DOI] [PubMed] [Google Scholar]
  36. Sallenave J. M., Marsden M. D., Ryle A. P. Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. Biol Chem Hoppe Seyler. 1992 Jan;373(1):27–33. doi: 10.1515/bchm3.1992.373.1.27. [DOI] [PubMed] [Google Scholar]
  37. Sallenave J. M., Ryle A. P. Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. Biol Chem Hoppe Seyler. 1991 Jan;372(1):13–21. doi: 10.1515/bchm3.1991.372.1.13. [DOI] [PubMed] [Google Scholar]
  38. Sallenave J. M., Shulmann J., Crossley J., Jordana M., Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994 Dec;11(6):733–741. doi: 10.1165/ajrcmb.11.6.7946401. [DOI] [PubMed] [Google Scholar]
  39. Sallenave J. M., Silva A. Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am J Respir Cell Mol Biol. 1993 Apr;8(4):439–445. doi: 10.1165/ajrcmb/8.4.439. [DOI] [PubMed] [Google Scholar]
  40. Sallenave J. M., Xing Z., Graham F., Gauldie J. In vivo adenovirus-mediated expression of human pre-elafin, a potent neutrophil elastase inhibitor. Chest. 1997 Jun;111(6 Suppl):128S–129S. doi: 10.1378/chest.111.6_supplement.128s. [DOI] [PubMed] [Google Scholar]
  41. Schalkwijk J., Chang A., Janssen P., De Jongh G. J., Mier P. D. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol. 1990 May;122(5):631–641. doi: 10.1111/j.1365-2133.1990.tb07285.x. [DOI] [PubMed] [Google Scholar]
  42. Schalkwijk J., de Roo C., de Jongh G. J. Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta. 1991 Feb 22;1096(2):148–154. doi: 10.1016/0925-4439(91)90053-c. [DOI] [PubMed] [Google Scholar]
  43. Schalkwijk J., van Vlijmen I. M., Alkemade J. A., de Jongh G. J. Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. J Invest Dermatol. 1993 Apr;100(4):390–393. doi: 10.1111/1523-1747.ep12471990. [DOI] [PubMed] [Google Scholar]
  44. Schiessler H., Arnhold M., Ohlsson K., Fritz H. Inhibitors of acrosin and granulocyte proteinases from human genital tract secretions. Hoppe Seylers Z Physiol Chem. 1976 Sep;357(9):1251–1260. doi: 10.1515/bchm2.1976.357.2.1251. [DOI] [PubMed] [Google Scholar]
  45. Schuler G. D., Boguski M. S., Stewart E. A., Stein L. D., Gyapay G., Rice K., White R. E., Rodriguez-Tomé P., Aggarwal A., Bajorek E. A gene map of the human genome. Science. 1996 Oct 25;274(5287):540–546. [PubMed] [Google Scholar]
  46. Smith C. E., Johnson D. A. Human bronchial leucocyte proteinase inhibitor. Rapid isolation and kinetic analysis with human leucocyte proteinases. Biochem J. 1985 Jan 15;225(2):463–472. doi: 10.1042/bj2250463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Starcher B., O'Neal P., Granstein R. D., Beissert S. Inhibition of neutrophil elastase suppresses the development of skin tumors in hairless mice. J Invest Dermatol. 1996 Aug;107(2):159–163. doi: 10.1111/1523-1747.ep12329559. [DOI] [PubMed] [Google Scholar]
  48. Steinert P. M., Marekov L. N. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem. 1995 Jul 28;270(30):17702–17711. doi: 10.1074/jbc.270.30.17702. [DOI] [PubMed] [Google Scholar]
  49. Streit V., Wiedow O., Bartels J., Christophers E. Antiprotease activity in urine of patients with inflammatory skin disorders. J Invest Dermatol. 1995 Oct;105(4):562–566. doi: 10.1111/1523-1747.ep12323460. [DOI] [PubMed] [Google Scholar]
  50. Tamechika I., Itakura M., Saruta Y., Furukawa M., Kato A., Tachibana S., Hirose S. Accelerated evolution in inhibitor domains of porcine elafin family members. J Biol Chem. 1996 Mar 22;271(12):7012–7018. doi: 10.1074/jbc.271.12.7012. [DOI] [PubMed] [Google Scholar]
  51. Thompson R. C., Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6692–6696. doi: 10.1073/pnas.83.18.6692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tiefenbacher C. P., Ebert M., Niroomand F., Batkai S., Tillmanns H., Zimmermann R., Kübler W. Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart. Pflugers Arch. 1997 Mar;433(5):563–570. doi: 10.1007/s004240050315. [DOI] [PubMed] [Google Scholar]
  53. Tsunemi M., Kato H., Nishiuchi Y., Kumagaye S., Sakakibara S. Synthesis and structure-activity relationships of elafin, an elastase-specific inhibitor. Biochem Biophys Res Commun. 1992 Jun 30;185(3):967–973. doi: 10.1016/0006-291x(92)91721-2. [DOI] [PubMed] [Google Scholar]
  54. Tsunemi M., Matsuura Y., Sakakibara S., Katsube Y. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Biochemistry. 1996 Sep 10;35(36):11570–11576. doi: 10.1021/bi960900l. [DOI] [PubMed] [Google Scholar]
  55. Tsunemi M., Matsuura Y., Sakakibara S., Katsube Y. Crystallization of a complex between an elastase-specific inhibitor elafin and porcine pancreatic elastase. J Mol Biol. 1993 Jul 5;232(1):310–311. doi: 10.1006/jmbi.1993.1387. [DOI] [PubMed] [Google Scholar]
  56. Ulvsbäck M., Lazure C., Lilja H., Spurr N. K., Rao V. V., Löffler C., Hansmann I., Lundwall A. Gene structure of semenogelin I and II. The predominant proteins in human semen are encoded by two homologous genes on chromosome 20. J Biol Chem. 1992 Sep 5;267(25):18080–18084. [PubMed] [Google Scholar]
  57. Van Ruissen F., de Jongh G. J., Zeeuwen P. L., Van Erp P. E., Madsen P., Schalkwijk J. Induction of normal and psoriatic phenotypes in submerged keratinocyte cultures. J Cell Physiol. 1996 Aug;168(2):442–452. doi: 10.1002/(SICI)1097-4652(199608)168:2<442::AID-JCP23>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  58. Walter M., Plotnick M., Schechter N. M. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin. Arch Biochem Biophys. 1996 Mar 1;327(1):81–88. doi: 10.1006/abbi.1996.0095. [DOI] [PubMed] [Google Scholar]
  59. Wiedow O., Lüdemann J., Utecht B., Christophers E. Inhibition of proteinase 3 activity by peptides derived from human epidermis. Adv Exp Med Biol. 1993;336:61–64. doi: 10.1007/978-1-4757-9182-2_8. [DOI] [PubMed] [Google Scholar]
  60. Wiedow O., Schröder J. M., Gregory H., Young J. A., Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990 Sep 5;265(25):14791–14795. [PubMed] [Google Scholar]
  61. Wiedow O., Wiese F., Christophers E. Lesional elastase activity in psoriasis. Diagnostic and prognostic significance. Arch Dermatol Res. 1995;287(7):632–635. doi: 10.1007/BF00371734. [DOI] [PubMed] [Google Scholar]
  62. Wiedow O., Wiese F., Streit V., Kalm C., Christophers E. Lesional elastase activity in psoriasis, contact dermatitis, and atopic dermatitis. J Invest Dermatol. 1992 Sep;99(3):306–309. doi: 10.1111/1523-1747.ep12616644. [DOI] [PubMed] [Google Scholar]
  63. Willems L. N., Otto-Verberne C. J., Kramps J. A., ten Have-Opbroek A. A., Dijkman J. H. Detection of antileukoprotease in connective tissue of the lung. Histochemistry. 1986;86(2):165–168. doi: 10.1007/BF00493382. [DOI] [PubMed] [Google Scholar]
  64. Ying Q. L., Kemme M., Simon S. R. Functions of the N-terminal domain of secretory leukoprotease inhibitor. Biochemistry. 1994 May 10;33(18):5445–5450. doi: 10.1021/bi00184a013. [DOI] [PubMed] [Google Scholar]
  65. Ying Q. L., Simon S. R. Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin. Biochemistry. 1993 Feb 23;32(7):1866–1874. doi: 10.1021/bi00058a021. [DOI] [PubMed] [Google Scholar]
  66. Zeeuwen P. L., Hendriks W., de Jong W. W., Schalkwijk J. Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family. Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature. J Biol Chem. 1997 Aug 15;272(33):20471–20478. doi: 10.1074/jbc.272.33.20471. [DOI] [PubMed] [Google Scholar]
  67. Zhang M., Magit D., Pardee A. B., Sager R. Re-expression of elafin in 21MT2 breast carcinomas by phorbol 12-myristate 13-acetate is mediated by the Ap1 site in the elafin promoter. Cancer Res. 1997 Oct 15;57(20):4631–4636. [PubMed] [Google Scholar]
  68. Zhang M., Zou Z., Maass N., Sager R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res. 1995 Jun 15;55(12):2537–2541. [PubMed] [Google Scholar]
  69. van Bergen B. H., Andriessen M. P., Spruijt K. I., van de Kerkhof P. C., Schalkwijk J. Expression of SKALP/elafin during wound healing in human skin. Arch Dermatol Res. 1996 Jul;288(8):458–462. doi: 10.1007/BF02505235. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES